WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm3 and 80–150-cm3 Prostates

David Dan Nguyen; Neil Barber; Mo Bidair; Peter Gilling; Paul Anderson; Kevin C. Zorn; Gopal Badlani; Mitch Humphreys; Steven Kaplan; Ronald Kaufman; Alan So; Ryan Paterson; Larry Goldenberg; Dean Elterman; Mihir Desai; Jim Lingeman; Claus Roehrborn; Naeem Bhojani

doi:10.1016/j.euros.2021.01.004

WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm³ and 80–150-cm³ Prostates

David Dan Nguyen, Neil Barber, Mo Bidair, Peter Gilling, Paul Anderson, Kevin C. Zorn, Gopal Badlani, Mitch Humphreys, Steven Kaplan, Ronald Kaufman, Alan So, Ryan Paterson, Larry Goldenberg, Dean Elterman, Mihir Desai, Jim Lingeman, Claus Roehrborn, Naeem Bhojani

Urology

Research output: Contribution to journal › Article › peer-review

Abstract

Comparing data from WATER and WATER II trials, we found that Aquablation is effective in patients with a prostate of 30–80 cm³ and patients with a prostate of 80–150 cm³ treated for lower urinary tract symptoms due to benign prostatic hyperplasia, with comparable outcomes in both groups. Functional outcome improvements are durable and retreatment rates are low at 2 yr of follow-up.

Original language	English (US)
Pages (from-to)	21-28
Number of pages	8
Journal	European Urology Open Science
Volume	25
DOIs	https://doi.org/10.1016/j.euros.2021.01.004
State	Published - Mar 2021

Keywords

Aquablation
Benign prostatic hyperplasia
Robotics

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euros.2021.01.004

Fingerprint Dive into the research topics of 'WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm<sup>3</sup> and 80–150-cm<sup>3</sup> Prostates'. Together they form a unique fingerprint.

Cite this

Nguyen, D. D., Barber, N., Bidair, M., Gilling, P., Anderson, P., Zorn, K. C., Badlani, G., Humphreys, M., Kaplan, S., Kaufman, R., So, A., Paterson, R., Goldenberg, L., Elterman, D., Desai, M., Lingeman, J., Roehrborn, C., & Bhojani, N. (2021). WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm³ and 80–150-cm³ Prostates. European Urology Open Science, 25, 21-28. https://doi.org/10.1016/j.euros.2021.01.004

WATER versus WATER II 2-Year Update : Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm³ and 80–150-cm³ Prostates. / Nguyen, David Dan; Barber, Neil; Bidair, Mo; Gilling, Peter; Anderson, Paul; Zorn, Kevin C.; Badlani, Gopal; Humphreys, Mitch; Kaplan, Steven; Kaufman, Ronald; So, Alan; Paterson, Ryan; Goldenberg, Larry; Elterman, Dean; Desai, Mihir; Lingeman, Jim; Roehrborn, Claus; Bhojani, Naeem.

In: European Urology Open Science, Vol. 25, 03.2021, p. 21-28.

Research output: Contribution to journal › Article › peer-review

Nguyen, DD, Barber, N, Bidair, M, Gilling, P, Anderson, P, Zorn, KC, Badlani, G, Humphreys, M, Kaplan, S, Kaufman, R, So, A, Paterson, R, Goldenberg, L, Elterman, D, Desai, M, Lingeman, J, Roehrborn, C & Bhojani, N 2021, 'WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm³ and 80–150-cm³ Prostates', European Urology Open Science, vol. 25, pp. 21-28. https://doi.org/10.1016/j.euros.2021.01.004

Nguyen, David Dan ; Barber, Neil ; Bidair, Mo ; Gilling, Peter ; Anderson, Paul ; Zorn, Kevin C. ; Badlani, Gopal ; Humphreys, Mitch ; Kaplan, Steven ; Kaufman, Ronald ; So, Alan ; Paterson, Ryan ; Goldenberg, Larry ; Elterman, Dean ; Desai, Mihir ; Lingeman, Jim ; Roehrborn, Claus ; Bhojani, Naeem. / WATER versus WATER II 2-Year Update : Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm³ and 80–150-cm³ Prostates. In: European Urology Open Science. 2021 ; Vol. 25. pp. 21-28.

@article{ba318e214673407e830dd7ff3dce7d3f,

title = "WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm3 and 80–150-cm3 Prostates",

abstract = "Comparing data from WATER and WATER II trials, we found that Aquablation is effective in patients with a prostate of 30–80 cm3 and patients with a prostate of 80–150 cm3 treated for lower urinary tract symptoms due to benign prostatic hyperplasia, with comparable outcomes in both groups. Functional outcome improvements are durable and retreatment rates are low at 2 yr of follow-up.",

keywords = "Aquablation, Benign prostatic hyperplasia, Robotics",

author = "Nguyen, {David Dan} and Neil Barber and Mo Bidair and Peter Gilling and Paul Anderson and Zorn, {Kevin C.} and Gopal Badlani and Mitch Humphreys and Steven Kaplan and Ronald Kaufman and Alan So and Ryan Paterson and Larry Goldenberg and Dean Elterman and Mihir Desai and Jim Lingeman and Claus Roehrborn and Naeem Bhojani",

year = "2021",

month = mar,

doi = "10.1016/j.euros.2021.01.004",

language = "English (US)",

volume = "25",

pages = "21--28",

journal = "European Urology Open Science",

issn = "2666-1691",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - WATER versus WATER II 2-Year Update

T2 - Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30–80-cm3 and 80–150-cm3 Prostates

AU - Nguyen, David Dan

AU - Barber, Neil

AU - Bidair, Mo

AU - Gilling, Peter

AU - Anderson, Paul

AU - Zorn, Kevin C.

AU - Badlani, Gopal

AU - Humphreys, Mitch

AU - Kaplan, Steven

AU - Kaufman, Ronald

AU - So, Alan

AU - Paterson, Ryan

AU - Goldenberg, Larry

AU - Elterman, Dean

AU - Desai, Mihir

AU - Lingeman, Jim

AU - Roehrborn, Claus

AU - Bhojani, Naeem

PY - 2021/3

Y1 - 2021/3

N2 - Comparing data from WATER and WATER II trials, we found that Aquablation is effective in patients with a prostate of 30–80 cm3 and patients with a prostate of 80–150 cm3 treated for lower urinary tract symptoms due to benign prostatic hyperplasia, with comparable outcomes in both groups. Functional outcome improvements are durable and retreatment rates are low at 2 yr of follow-up.

AB - Comparing data from WATER and WATER II trials, we found that Aquablation is effective in patients with a prostate of 30–80 cm3 and patients with a prostate of 80–150 cm3 treated for lower urinary tract symptoms due to benign prostatic hyperplasia, with comparable outcomes in both groups. Functional outcome improvements are durable and retreatment rates are low at 2 yr of follow-up.

KW - Aquablation

KW - Benign prostatic hyperplasia

KW - Robotics

UR - http://www.scopus.com/inward/record.url?scp=85100393853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100393853&partnerID=8YFLogxK

U2 - 10.1016/j.euros.2021.01.004

DO - 10.1016/j.euros.2021.01.004

M3 - Article

AN - SCOPUS:85100393853

VL - 25

SP - 21

EP - 28

JO - European Urology Open Science

JF - European Urology Open Science

SN - 2666-1691

ER -